

Amendments to the Claims

Claims 1-10 (canceled)

Claim ¹~~11~~ (previously presented): A method for inhibiting or preventing T cell/B cell interactions associated with Crohn's disease comprising administering an amount of a monoclonal anti-CD80 antibody or a CD80-binding fragment thereof sufficient to inhibit the binding of B cells and T cells via the CD80/CD28 pathway; wherein said monoclonal antibody or fragment thereof binds specifically to CD80 antigen without inhibiting the binding of CD80 antigen to CTLA-4.

DI
~~8~~
Claim ²~~12~~ (previously presented): The method of Claim ¹~~11~~, wherein said anti-CD80 antibody is a human monoclonal antibody, or a chimeric antibody comprising variable regions of a non-human anti-CD80 antibody and human constant regions.

[Claims 13-18 (canceled)]

Claim ³~~19~~ (previously presented): The method of Claim ¹~~11~~, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10 or antibody 16C10.

Claim ⁴~~20~~ (previously presented): The method of Claim ²~~12~~, wherein said anti-CD80 antibody is a chimeric antibody comprising variable regions of an Old World monkey antibody and human constant regions.

[Claims 21-26 (canceled)]

⁵
Claim ⁵~~27~~ (previously presented): A method of treating Crohn's disease in a subject in need of such treatment by administering a therapeutically effective amount of a monoclonal anti-CD80 antibody or a CD80-binding fragment thereof that does not inhibit the CD80/CTLA-4 binding interaction.

⁶
Claim ⁵~~28~~ (previously presented): The method of Claim ⁵~~27~~, comprising administering a human monoclonal anti-CD80 antibody, or a chimeric antibody comprising variable regions of a non-human anti-CD80 antibody and human constant regions.

⁷
Claim ~~29~~ (previously presented): The method of Claim ⁶~~28~~, comprising administering a chimeric anti-CD80 antibody comprising variable regions of an Old World monkey antibody and human constant regions.

⁸
Claim ~~30~~ (currently amended): The method of Claim ¹~~11~~, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunomodulator selected from the group consisting of IL-7, IL-10, CTLA4-Ig, soluble CTLA-4, an anti-CD28 antibody ~~or fragment thereof~~, and a CD28-binding fragment of an anti-CD28 antibody.

⁹
Claim ~~31~~ (currently amended): The method of Claim ⁵~~27~~, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunomodulator selected from the group consisting of IL-7, IL-10, CTLA4-Ig, soluble CTLA-4, an anti-CD28 antibody ~~or fragment thereof~~, and a CD28-binding fragment of an anti-CD28 antibody.

¹⁰
Claim ~~32~~ (previously presented): The method of Claim ¹~~11~~, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunosuppressant selected from the group consisting of cyclosporin A, FK506, anti-TNF α , anti-CD54, anti-CD11, anti-CD11a, anti-IL-1, TNF α receptor, and IL-1 receptor.

¹¹
Claim ~~33~~ (previously presented): The method of Claim ⁵~~27~~, wherein said anti-CD80 antibody or CD80-binding fragment thereof is administered in combination with an immunosuppressant selected from the group consisting of cyclosporin A, FK506, anti-TNF α , anti-CD54, anti-CD11, anti-CD11a, anti-IL-1, TNF α receptor, and IL-1 receptor.

¹²
Claim ~~34~~ (previously presented): The method of Claim ⁴~~20~~, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10 or antibody 16C10.

¹³
Claim ~~35~~ (previously presented): The method of Claim ⁴~~20~~, wherein said anti-CD80 antibody is a chimeric antibody comprising variable regions of antibody 7C10 or antibody 16C10.

¹⁴
Claim ~~36~~ (previously presented): The method of Claim ¹³~~35~~, wherein said chimeric anti-CD80 antibody comprises a human constant region selected from the group consisting of human gamma 1 constant region, human gamma 4 constant region, and human gamma 4 PE constant region.

¹⁵
Claim ~~37~~ (previously presented): The method of Claim ¹³~~35~~, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 3a (SEQ ID NO:1) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 3b and 3c (SEQ ID NO:3).

¹⁶
Claim ~~38~~ (previously presented): The method of Claim ¹³~~35~~, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 5a (SEQ ID NO:9) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 5b and 5c (SEQ ID NO:11).

¹⁷
Claim ~~39~~ (previously presented): The method of Claim ¹⁴~~36~~, wherein said chimeric anti-CD80 antibody comprises variable regions of antibody 16C10 and a human gamma 1 constant region.

¹⁸
Claim ~~40~~ (previously presented): The method of Claim ¹~~41~~, comprising administering a CD80-binding fragment of a monoclonal antibody that binds specifically to CD80 antigen without inhibiting the binding of CD80 antigen to CTLA-4.

¹⁹
Claim ~~41~~ (previously presented): The method of Claim ¹⁸~~40~~, wherein said CD80-binding antibody fragment is selected from the group consisting of Fab, F(ab')₂, and Fv.

²⁰
Claim ~~42~~ (previously presented): The method of Claim ¹⁸~~40~~, wherein said CD80-binding antibody fragment competes for binding to CD80 antigen with antibody 7C10 or antibody 16C10.

²¹
Claim ~~43~~ (previously presented): The method of Claim ¹⁸~~40~~, wherein said CD80-binding antibody fragment comprises variable regions of an Old World monkey antibody.

²²
Claim ~~44~~ (previously presented): The method of Claim ²¹~~43~~, wherein said CD80-binding antibody fragment comprises variable regions of antibody 7C10 or antibody 16C10.

²³
Claim ~~45~~ (previously presented): The method of Claim ⁵~~27~~, wherein said anti-CD80 antibody competes for binding to CD80 antigen with antibody 7C10 or antibody 16C10.

²⁴
Claim ~~46~~ (previously presented): The method of Claim ⁷~~29~~, wherein said chimeric anti-CD80 antibody comprises variable regions of antibody 7C10 or antibody 16C10.

Claim ²⁵~~47~~ (previously presented): The method of Claim ²⁴~~46~~, wherein said chimeric anti-CD80 antibody comprises a human constant region selected from the group consisting of human gamma 1 constant region, human gamma 4 constant region, and human gamma 4 PE constant region.

Claim ²⁶~~48~~ (previously presented): The method of Claim ²⁴~~46~~, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 3a (SEQ ID NO:1) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 3b and 3c (SEQ ID NO:3).

Claim ²⁷~~49~~ (previously presented): The method of Claim ²⁴~~46~~, wherein the light chain of said anti-CD80 antibody has the amino acid sequence shown in Fig. 5a (SEQ ID NO:9) and the heavy chain of said anti-CD80 antibody has the amino acid sequence shown in Figs. 5b and 5c (SEQ ID NO:11).

Claim ²⁸~~50~~ (previously presented): The method of Claim ²⁵~~47~~, wherein said anti-CD80 antibody comprises variable regions of antibody 16C10 and a human gamma 1 constant region.

Claim ²⁹~~51~~ (previously presented): The method of Claim ⁵~~27~~, comprising administering a CD80-binding fragment of a monoclonal antibody that does not inhibit the CD80/CTLA-4 binding interaction.

Claim ³⁰~~52~~ (previously presented): The method of Claim ²⁹~~51~~, wherein said CD80-binding antibody fragment is selected from the group consisting of Fab, F(ab')₂, and Fv.

Claim ³¹~~53~~ (previously presented): The method of Claim ²⁹~~51~~, wherein said CD80-binding antibody fragment competes for binding to CD80 antigen with antibody 7C10 or antibody 16C10.

Claim ³²~~54~~ (previously presented): The method of Claim ²⁹~~51~~, wherein said CD80-binding antibody fragment comprises variable regions of an Old World monkey antibody.

Claim ³³~~55~~ (previously presented): The method of Claim ³²~~54~~, wherein said CD80-binding antibody fragment comprises variable regions of antibody 7C10 or antibody 16C10.